Page last updated: 2024-09-05

tesaglitazar and ns-220

tesaglitazar has been researched along with ns-220 in 1 studies

Compound Research Comparison

Studies (tesaglitazar)	Trials (tesaglitazar)	Recent Studies (post-2010) (tesaglitazar)	Studies (ns-220)	Trials (ns-220)	Recent Studies (post-2010) (ns-220)
74	13	25	5	0	1

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Basu, S; Giri, S; Godha, A; Goel, A; Goswami, A; Jain, M; Makadia, P; Patel, H; Patel, M; Patel, P; Patil, P; Pingali, H; Shah, S; Zaware, P	1

Other Studies

1 other study(ies) available for tesaglitazar and ns-220

Article	Year
Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. Bioorganic & medicinal chemistry letters, 2008, Oct-15, Volume: 18, Issue:20 Topics: Animals; Carboxylic Acids; Diabetes Mellitus, Type 2; Dioxanes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Mesylates; Mice; Models, Chemical; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Transcriptional Activation	2008

Article

Year

Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.

Bioorganic & medicinal chemistry letters, 2008, Oct-15, Volume: 18, Issue:20

Topics: Animals; Carboxylic Acids; Diabetes Mellitus, Type 2; Dioxanes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Mesylates; Mice; Models, Chemical; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Transcriptional Activation

2008